Catalog: | C-FC-3627A |
Product Type: | FCM Antibody |
Size: | 50 µL/100 µL |
Reactivity: | Human |
Specificity: | Human BACE1 |
Analysis mode: | FCM,ICC/IF |
Host: | Rabbit |
Clonality: | Monoclonal |
Isotype: | IgG |
Alternate names: | beta-site APP-cleaving enzyme 1 |
Form: | Liquid |
Shipping: | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Storage: | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Purification method: | Protein A |
Conjugation: | Unconjugated |
Immunogen: | Recombinant Human BACE1 protein |
Buffer: | 0.2 μm filtered solution in PBS |
Beta-site APP-cleaving enzyme 1 (BACE1) is an aspartic-acid protease important in the formation of myelin sheaths in peripheral nerve cells. In the brain, This protein is expressed highly in the substantia nigra, locus coruleus and medulla oblongata. Strong BACE1 expression has also been described in pancreatic tissue. BACE1 has a pivotal role in the pathogenesis of Alzheimer's disease. In Alzheimer's disease patients, BACE1 levels were elevated although mRNA levels were not changed. It has been found that BACE1 gene expression is controlled by a TATA-less promoter. The translational repression as a new mechanism controlling its expression. And the low concentrations of Ca(2+) (microM range) significantly increased the proteolytic activity of BACE1. Furthermore, BACE1 protein is ubiquitinated, and the degradation of BACE1 proteins and amyloid precursor protein processing are regulated by the ubiquitin-proteasome pathway. It has also been identified as the rate limiting enzyme for amyloid-beta-peptide (Abeta) production.
Copyright © 2025 Creative Biogene. All rights reserved.